A number of firms have modified their ratings and price targets on shares of Neurocrine Biosciences (NASDAQ: NBIX) recently:8/4/2026 – Neurocrine Biosciences was downgraded by Zacks Research from “strong-buy” to “hold”. 7/31/2026 – Neurocrine Biosciences had its price target raised by Citigroup Inc. from $246.00 to $249.00. 7/31/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $195.00 to $198.00. Get Neurocrine Biosciences Inc alerts:Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Featured StoriesReceive News & Ratings for Neurocrine Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.